Skip to content
Review

T cell-based immunotherapy in solid tumors: mechanistic barriers and emerging opportunities.

Aug 2026 · BMB Reports · 0 citations
Medicine

TL;DR

Developing a mechanistic framework that combines intrinsic T cell reprogramming with adaptation to the tumor context will be crucial for extending durable T cell-mediated immunity to solid cancers.

View source

Similar papers

Review Open access Aug 2026

Reprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance

The biological mechanisms underlying resistance to CAR-T therapy in solid tumors are examined and emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity are critically evaluated.

Wei Cheng, Mei-Lan Liu, Yu-Hua Diao et al. · 0 citations
Review Open access Aug 2026

Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions

This review offers a comprehensive framework for understanding and surmounting immunosuppressive barriers in cancer therapy and develops systematic synergistic strategies such as multi-pathway checkpoint blockade, ADC-immunotherapy combinations, temporally and spatially optimized conventional therapies, and targeted ag...

Meng-Meng Liu, Yi-Chen Zhu, He-Miao Liang et al. · 0 citations
#gene editing Review Open access Sep 2026

Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases

This review synthesizes recent advances in molecular engineering strategies that enhance CAR-T cell function beyond conventional receptor design and discusses how receptor engineering, genome editing, transcriptional and epigenetic regulation, metabolic reprogramming, synthetic gene circuits, and safety-control platfor...

Hany E. Marei, G. Pozzoli, S. Caratelli et al. · 0 citations
Review Open access Jul 2026

CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers

This review systematically outlines multifactorial barriers within the lung cancer TME and discusses emerging strategies, including combinatorial approaches, engineered CAR T designs, and microenvironment-modulating platforms, that aim to improve the therapeutic efficacy of CAR T cell therapy in lung cancer.

Lu Liu, Dan-Dan Liang, Cui Wang et al. · 0 citations
Review Open access Aug 2026

How diverse therapeutic strategies reshape the tumor immune microenvironment in small cell lung cancer: from radiation to engineered immunotherapies.

Small cell lung cancer (SCLC) is an aggressive and immunologically "cold" malignancy characterized by profound immunosuppression and limited responsiveness to immunotherapy. Its tumor immune microenvironment (TIME) exhibits defective antigen presentation, suppressive cytokine signaling, and abnormal stromal-metabolic i...

Zhuoyan Han, Jie Tong, Ya-Ling Feng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.